Keryx Biopharm Inc (KERX) 6.20 $KERX
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.29 (+0.06), SCYX: 2.19 (-0.04), CFRX: 2.98 (+0.01), MNTA: 10.97 (+0.34), KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Has Returned 37.7% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Fri Jun 17, 12:55PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 37.73% as of today's recent price of $6.18.
KERX: 6.20 (+0.19)
Shares of KERX Up 34.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:31AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 34.89% as of today's recent price of $6.05.
KERX: 6.20 (+0.19)
Shares of KERX Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:04PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 53.85% as of today's recent price of $6.90.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Up 22.4% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed May 18, 1:20PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 22.41% as of today's recent price of $5.49.
KERX: 6.20 (+0.19)
Uptrend Call Working As Keryx Biopharmaceuticals Stock Rises 27.1% (KERX)
Comtex SmarTrend(R) - Tue May 03, 12:56PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 2 months, Keryx Biopharmaceuticals has returned 27.09% as of today's recent price of $5.70.
KERX: 6.20 (+0.19)
Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 180.29 (+4.91), ARQL: 1.92 (+0.03), AEGR: 1.67 (+0.11), KERX: 6.20 (+0.19)
Keryx Biopharma reports 1Q loss
Automated Insights - Thu Apr 28, 8:31AM CDT
BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a loss of $41 million in its first quarter.
KERX: 6.20 (+0.19)
3 Healthcare Stocks Billionaires Love Right Now
Brian Feroldi, Keith Speights, and Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 28, 8:04AM CDT
Source: BILL BROOKS, FLICKR CREATIVE COMMONS. 13F reports are filed with the Securities and Exchange Commission by billionaire investors each quarter and make it easy for anyone to track their trades and see what they've been buying and selling...
MRK: 57.68 (+0.64), MYL: 46.16 (+1.16), KERX: 6.20 (+0.19)
Keryx (KERX) Reports Wider-Than-Expected Loss in Q1
Ekta Bagri - Zacks Investment Research - Thu Apr 28, 6:46AM CDT
Keryx (KERX) reported a wider-than-expected loss in the first quarter of 2016 but maintained its outlook for 2016.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:04AM CDT
-- Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia(TM) (ferric citrate) net U.S. product sales
KERX: 6.20 (+0.19)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.20 (+0.15), BIIB: 238.62 (+4.02), JNJ: 117.38 (+0.92), BMRN: 83.65 (+1.47), SHPG: 180.29 (+4.91), IMGN: 3.32 (+0.07), BXLT: 46.02 (-0.18), KERX: 6.20 (+0.19), NVS: 80.67 (+0.96)
What's in Store for Keryx (KERX) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 8:50AM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is scheduled to report first-quarter 2016 results on Apr 28.
BMRN: 83.65 (+1.47), GILD: 83.37 (+0.92), SNY: 41.19 (+0.90), KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2016 Financial Results on Thursday, April 28, 2016
GlobeNewswire - Thu Apr 14, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, April 28, 2016 at 8:00 a.m. ET to discuss its first quarter 2016 financial results.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
GlobeNewswire - Fri Apr 01, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced appointment of two industry leaders to Keryx's board of directors, which increases the size of the company's board to 10 members. These appointments are expected to bring deep, relevant industry experience to Keryx at an important time in the company's growth.
VCEL: 2.29 (+0.06), SCYX: 2.19 (-0.04), CFRX: 2.98 (+0.01), ACOR: 26.31 (+1.04), KERX: 6.20 (+0.19)
Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:20PM CDT
Shares of Keryx Biopharmaceuticals, Inc. (KERX) climbed 8.57% after the company announced positive top-line results from its phase III study on Auryxia (ferric citrate).
ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15), KERX: 6.20 (+0.19)
Watch for Keryx Biopharmaceuticals to Potentially Pullback After Gaining 14.29% Yesterday
Comtex SmarTrend(R) - Tue Mar 29, 3:07PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $5.11 to a high of $5.74. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $4.91 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
KERX: 6.20 (+0.19)
Why is Keryx Biopharma Stock (KERX) Soaring Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:56PM CDT
Keryx Biopharmaceuticals Inc. is having a quality day of trading. What is causing the stock to be up?
KERX: 6.20 (+0.19)
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.29 (+0.06), SCYX: 2.19 (-0.04), CFRX: 2.98 (+0.01), MNTA: 10.97 (+0.34), KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Has Returned 37.7% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Fri Jun 17, 12:55PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 37.73% as of today's recent price of $6.18.
KERX: 6.20 (+0.19)
Shares of KERX Up 34.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:31AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 34.89% as of today's recent price of $6.05.
KERX: 6.20 (+0.19)
Shares of KERX Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:04PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 53.85% as of today's recent price of $6.90.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Up 22.4% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed May 18, 1:20PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 22.41% as of today's recent price of $5.49.
KERX: 6.20 (+0.19)
Uptrend Call Working As Keryx Biopharmaceuticals Stock Rises 27.1% (KERX)
Comtex SmarTrend(R) - Tue May 03, 12:56PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 2 months, Keryx Biopharmaceuticals has returned 27.09% as of today's recent price of $5.70.
KERX: 6.20 (+0.19)
Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 180.29 (+4.91), ARQL: 1.92 (+0.03), AEGR: 1.67 (+0.11), KERX: 6.20 (+0.19)
Keryx Biopharma reports 1Q loss
Automated Insights - Thu Apr 28, 8:31AM CDT
BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a loss of $41 million in its first quarter.
KERX: 6.20 (+0.19)
3 Healthcare Stocks Billionaires Love Right Now
Brian Feroldi, Keith Speights, and Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 28, 8:04AM CDT
Source: BILL BROOKS, FLICKR CREATIVE COMMONS. 13F reports are filed with the Securities and Exchange Commission by billionaire investors each quarter and make it easy for anyone to track their trades and see what they've been buying and selling...
MRK: 57.68 (+0.64), MYL: 46.16 (+1.16), KERX: 6.20 (+0.19)
Keryx (KERX) Reports Wider-Than-Expected Loss in Q1
Ekta Bagri - Zacks Investment Research - Thu Apr 28, 6:46AM CDT
Keryx (KERX) reported a wider-than-expected loss in the first quarter of 2016 but maintained its outlook for 2016.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:04AM CDT
-- Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia(TM) (ferric citrate) net U.S. product sales
KERX: 6.20 (+0.19)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.20 (+0.15), BIIB: 238.62 (+4.02), JNJ: 117.38 (+0.92), BMRN: 83.65 (+1.47), SHPG: 180.29 (+4.91), IMGN: 3.32 (+0.07), BXLT: 46.02 (-0.18), KERX: 6.20 (+0.19), NVS: 80.67 (+0.96)
What's in Store for Keryx (KERX) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 8:50AM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is scheduled to report first-quarter 2016 results on Apr 28.
BMRN: 83.65 (+1.47), GILD: 83.37 (+0.92), SNY: 41.19 (+0.90), KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2016 Financial Results on Thursday, April 28, 2016
GlobeNewswire - Thu Apr 14, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, April 28, 2016 at 8:00 a.m. ET to discuss its first quarter 2016 financial results.
KERX: 6.20 (+0.19)
Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
GlobeNewswire - Fri Apr 01, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced appointment of two industry leaders to Keryx's board of directors, which increases the size of the company's board to 10 members. These appointments are expected to bring deep, relevant industry experience to Keryx at an important time in the company's growth.
VCEL: 2.29 (+0.06), SCYX: 2.19 (-0.04), CFRX: 2.98 (+0.01), ACOR: 26.31 (+1.04), KERX: 6.20 (+0.19)
Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:20PM CDT
Shares of Keryx Biopharmaceuticals, Inc. (KERX) climbed 8.57% after the company announced positive top-line results from its phase III study on Auryxia (ferric citrate).
ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15), KERX: 6.20 (+0.19)
Watch for Keryx Biopharmaceuticals to Potentially Pullback After Gaining 14.29% Yesterday
Comtex SmarTrend(R) - Tue Mar 29, 3:07PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $5.11 to a high of $5.74. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $4.91 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
KERX: 6.20 (+0.19)
Why is Keryx Biopharma Stock (KERX) Soaring Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:56PM CDT
Keryx Biopharmaceuticals Inc. is having a quality day of trading. What is causing the stock to be up?
KERX: 6.20 (+0.19)
